新诺威(300765.SZ)控股子公司对外授权药物获得美国FDA快速通道资格

智通财经12-04

智通财经APP讯，新诺威(300765.SZ)发布公告，公司控股子公司石药集团巨石生物制药有限公司授权给 Corbus Pharmaceuticals, Inc.(以下简称“Corbus”)开发的 CRB-701(SYS6002)被美国食品药品监督管理局(简称“美国FDA”)授予快速通道资格，用于治疗复发或难治性转移性宫颈癌。美国 FDA 快速通道资格旨在促进拟用于治疗严重疾病及具有填补未满足医疗...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2488155970?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-12-04 16:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2488155970","market":"sh","top_or_hot":-1,"title":"新诺威(300765.SZ)控股子公司对外授权药物获得美国FDA快速通道资格","media":"智通财经","content":"<div>\n<p>智通财经APP讯，新诺威(300765.SZ)发布公告，公司控股子公司石药集团巨石生物制药有限公司授权给 Corbus Pharmaceuticals, Inc.(以下简称“Corbus”)开发的 CRB-701(SYS6002)被美国食品药品监督管理局(简称“美国FDA”)授予快速通道资格，用于治疗复发或难治性转移性宫颈癌。美国 FDA 快速通道资格旨在促进拟用于治疗严重疾病及具有填补未满足医疗...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1220205.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>新诺威(300765.SZ)控股子公司对外授权药物获得美国FDA快速通道资格</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n新诺威(300765.SZ)控股子公司对外授权药物获得美国FDA快速通道资格\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-04 16:05 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1220205.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，新诺威(300765.SZ)发布公告，公司控股子公司石药集团巨石生物制药有限公司授权给 Corbus Pharmaceuticals, Inc.(以下简称“Corbus”)开发的 CRB-701(SYS6002)被美国食品药品监督管理局(简称“美国FDA”)授予快速通道资格，用于治疗复发或难治性转移性宫颈癌。美国 FDA 快速通道资格旨在促进拟用于治疗严重疾病及具有填补未满足医疗...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1220205.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"300765","symbol_name":"新诺威","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1220205.html","article_id":"2488155970","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2488155970","pubTimestamp":1733299558,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，新诺威(300765.SZ)发布公告，公司控股子公司石药集团巨石生物制药有限公司授权给 Corbus Pharmaceuticals, Inc.(以下简称“Corbus”)开发的 CRB-701(SYS6002)被美国食品药品监督管理局(简称“美国FDA”)授予快速通道资格，用于治疗复发或难治性转移性宫颈癌。美国 FDA 快速通道资格旨在促进拟用于治疗严重疾病及具有填补未满足医疗需求潜力的药物的开发，并加快审评。该产品取得美国FDA 快速通道资格有助于加快药物后续研发和批准上市等里程碑事件实现。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"300765":"新诺威","BK0226":"食品制造"},"translate_title":"The external authorized drugs of the holding subsidiary of Xinnuowei (300765. SZ) obtained the US FDA fast track qualification","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300765":1},"content_text":"智通财经APP讯，新诺威(300765.SZ)发布公告，公司控股子公司石药集团巨石生物制药有限公司授权给 Corbus Pharmaceuticals, Inc.(以下简称“Corbus”)开发的 CRB-701(SYS6002)被美国食品药品监督管理局(简称“美国FDA”)授予快速通道资格，用于治疗复发或难治性转移性宫颈癌。美国 FDA 快速通道资格旨在促进拟用于治疗严重疾病及具有填补未满足医疗需求潜力的药物的开发，并加快审评。该产品取得美国FDA 快速通道资格有助于加快药物后续研发和批准上市等里程碑事件实现。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2488155970"}